Locations
San Francisco, CA, USA · Austin, TX, USA · West University, Austin, TX, USA
industry
Pharmaceuticals
Size
11-50 employees
Stage
Other
founded in
2016
Next generation anti-infectives that mimic natural human antimicrobial peptides. Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class Claromer™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by U.S. government-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profile.
Is this your company?
Something looks off?
On-site & Remote